A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Crizotinib (Primary) ; Erlotinib (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 21 Dec 2017 Status changed from recruiting to active, no longer recruiting.